Answers are grounded in this paper and cite their sources.
The psychometric properties of the GHD-CTB-Child, GHD-CTB-Observer, and GHD-PTB support the validity of their use as PRO and ObsRO measures to capture the experiences associated with treatment burden for children with GHD and their parents/guardians in both clinical and research settings. The Clinicaltrials.gov registration number NCT02580032 was first posted October 20, 2015.
No takes yet. Share an insight, caveat, or question.
Brod et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: